Case Report
Copyright ©The Author(s) 2021.
World J Clin Cases. Oct 26, 2021; 9(30): 9236-9243
Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9236
Table 1 Clinical features and chest computed tomography results of six patients with pulmonary enteric adenocarcinoma
Case
Gender
Age (yr)
Smoking history
Chief complaints
Lesion location
Mass size (cm)
Metastatic lymph node
Metastatic locations
Tumor stage
OS (mo)
1Male61-Weakness of left limb, numbness of left facePosterior segment of RLL3.6 × 2.8Hilar and mediastinalIntracranialregionT2N2M1Lost to follow-up
2Female73-A lung mass found by imaging studies with slightly coughPosterior segment of LLL2.8 × 1.5--T2N0M0Lost to follow-up
3Female59-A lungmass found by imaging studiesLLL1.3 × 0.6--T1N0M0> 58
4Female64-Pain of right chest and backRUL2.1 × 2.0MediastinalRight pleuraT1N2M1Lost to follow-up
5Female59-Cough with feverBilateral2.7 × 1.5-Intra-pulmonaryT4N0M1> 9
6Female68-Cough,expect-ration, pain of left lower limb with difficult walkingRLL6.7 × 5.4MediastinumIntra-pulmonary + intracranialregionT4N2M1> 7
Table 2 Serum tumor markers of six patients with pulmonary enteric adenocarcinoma
Case
CEA (ng/mL)
CA199 (U/mL)
CA125 (U/mL)
133.540.833.5
22.45.87.4
31.72.69.3
4509132.6217.8
52.7243.613.7
61.11449.917
Table 3 Immunohistochemical results of six patients with pulmonary enteric adenocarcinoma
Case
CDX2
CK20
CK7
TTF-1
Napsin A
ALK-lung
Others
1++---Not testedNot tested
2--+--Not testedSPA (-)
3+Not tested--Not testedNot testedCK19 (+), SPA (-)
4++/-+---p63 (-), CK5/6 (-), PAX8 (-)
5+Not tested+---CD20 (-), MUC2 (-)
6+-+---Ki-67 (low)
Table 4 Genetic testing results of four patients with pulmonary enteric adenocarcinoma
Case
ALK
BRAF
BRCA1
BRCA2
EGFR
ERBB2
KRAS
ROS1
TMB (/Mb)
3------+-6.3
4--------6.3
5--+---+-10.3
6-----+--13.5
Table 5 Treatment for six patients with pulmonary enteric adenocarcinoma
Case
Lesion location
Treatment
1Posterior segment of RLLGamma knife for intracranial metastases, with 4 times of pemetrexed + cisplatin, 3 courses of ENDOSTAR, 30 times of radiotherapy, and tumor evaluation was PR; gamma knife again for new intracranial metastases on November 19, 2013
2Posterior segment of LLLNo treatment
3LLLSurgical resection first, reoperation of the resection region because of relapse in September 2015, and no recurrence evidence
4RULNo treatment
5BilateralTC chemotherapy and bevacizumab, tumor evaluation was SD
6RLLGamma knife + chemotherapy (pemetrexed + carboplatin), tumor evaluation was SD